In vivo antitumor activity demonstrated with squamous carcinoma reactive monoclonal antibody-Vinca immunoconjugates.
An immunoconjugate (PF1/D-DAVLBHYD), made with the squamous carcinoma reactive monoclonal antibody PF1/D and a derivative of vinblastine, DAVLBHYD, was shown to suppress established T222 human tumor nude mouse xenografts using a multidose protocol. Treatments of xenograft-bearing mice with free drug, free antibody, or a mixture of the two, were unsuccessful at achieving suppression without associated toxicity, using otherwise identical protocols. A Vinca conjugate with a related squamous carcinoma reactive monoclonal antibody, PF1/B, was shown to have similar tumor suppressive activity. In a dual immunoconjugate therapy protocol, PF1/D-DAVLBHYD and PF1/B-DAVLBHYD had additive antitumor effects which were consistent with their complementary tumor reactivity.
Johnson
D A
DA
Lilly Research Laboratories, Eli Lilly and Co., Indianapolis, In 46285.
Zimmermann
J L
JL
Laguzza
B C
BC
Eble
J N
JN
D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D000912:Antibodies, Neoplasm / Q000008:administration & dosage*; D002294:Carcinoma, Squamous Cell / Q000276:immunology / Q000628:therapy*; D002460:Cell Line; D006801:Humans; D008175:Lung Neoplasms / Q000628:therapy*; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D014183:Transplantation, Heterologous; D014750:Vincristine / Q000008:administration & dosage* / Q000031:analogs & derivatives*
D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; D014750:Vincristine